OUTLOOK THERAPEUTICS INC
$ 0.41
2.75%
24 Feb - close price
- Market Cap 30,212,400 USD
- Current Price $ 0.41
- High / Low $ 0.43 / 0.40
- Stock P/E N/A
- Book Value -0.60
- EPS -2.89
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -2.09 %
- ROE -0.04 %
- 52 Week High 3.39
- 52 Week Low 0.38
About
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Analyst Target Price
$5.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-12-19 | 2025-08-14 | 2025-05-14 | 2025-02-12 | 2024-12-20 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-22 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.22 | -0.28 | -0.55 | -0.3365 | -0.89 | -0.9369 | -0.83 | -1.55 | -0.04 | -0.05 | -0.08 | -0.03 |
| Estimated EPS | -0.1733 | -0.06 | -0.06 | -0.5533 | -0.52 | -0.9 | -1.01 | -0.85 | -0.05 | -0.06 | -0.05 | -0.06 |
| Surprise | -0.0467 | -0.22 | -0.49 | 0.2168 | -0.37 | -0.0369 | 0.18 | -0.7 | 0.01 | 0.01 | -0.03 | 0.03 |
| Surprise Percentage | -26.9475% | -366.6667% | -816.6667% | 39.1831% | -71.1538% | -4.1% | 17.8218% | -82.3529% | 20% | 16.6667% | -60% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OTLK
2026-02-19 21:53:57
Outlook Therapeutics has signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland. This partnership aims to expand the availability of LYTENAVA™ in Europe for the treatment of retina diseases, particularly wet AMD, with a projected launch in Switzerland in 2027. Mediconsult AG will handle marketing, distribution, and regulatory activities in Switzerland, while Outlook Therapeutics will manage manufacturing and product supply.
2026-02-19 14:58:11
Outlook Therapeutics is seeking to break a cycle of FDA rejections for its ophthalmic bevacizumab. The company considers the latest Complete Response Letter (CRL) "unexpected" and "inconsistent" with existing evidence. They are planning a fresh meeting with the FDA to address these concerns.
2026-02-19 14:28:15
Outlook Therapeutics has signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland. Under this partnership, Mediconsult will handle marketing, distribution, and regulatory activities for LYTENAVA™ in Switzerland, with a planned launch in 2027. This collaboration aims to expand the European footprint of LYTENAVA™, an ophthalmic formulation of bevacizumab designed for retina diseases.
2026-02-18 23:27:57
Outlook Therapeutics (OTLK) has received a notice from Nasdaq for noncompliance, as its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until August 17, 2026, to regain compliance or face potential delisting, and management is considering options to maintain its Nasdaq listing. Analysts currently rate OTLK as a Hold with a $0.41 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial fundamentals and bearish technicals.
2026-02-18 22:27:57
Outlook Therapeutics (OTLK) has received a notice from Nasdaq for failing to maintain the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until August 17, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days. Failure to comply could lead to delisting, though the company may qualify for an extension.
2026-02-18 03:27:58
Outlook Therapeutics reported its Q1 fiscal year 2026 financial results, including an increased net loss compared to the prior year. The company is expanding its LYTENAVA™ (bevacizumab gamma) sales in Europe, with Austria launched in January 2026 and further launches planned. Additionally, Outlook Therapeutics submitted a Type A meeting request to the FDA to address the Complete Response Letter for ONS-5010 regarding its U.S. regulatory path.
